Aurobindo Pharma arm CuraTeQ Biologics completes successful Phase 1 Pharmacokinetics study of bone drug Ruchika Sharma10 April 2025 11:56 AM ISTDenosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the cells that break down bone.
Alvotech, Dr Reddy's collaborate for commercialization of AVT03 in US, Europe and UK Ruchika Sharma23 May 2024 12:16 PM ISTHyderabad: Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
USFDA adds boxed warning for Amgen bone loss drug Prolia Ruchika Sharma22 Jan 2024 2:30 PM ISTNew Delhi: The U.S. Food and Drug Administration added a serious warning on the prescribing information for Amgen's drug Prolia to treat bone...
Lupin Gets CDSCO Panel Nod To study osteoporosis drug Denosumab Dr. Divya Colin4 Aug 2023 6:00 PM ISTNew Delhi: The drug major Lupin has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
EMA accepts marketing authorization applications for proposed biosimilar Denosumab: Sandoz Ruchika Sharma28 May 2023 10:00 AM ISTDenosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone...
Patent infringement: Amgen sues Novartis to block generic osteoporosis, bone cancer drugs Ruchika Sharma3 May 2023 5:30 PM ISTAmgen said the proposed biosimilars infringe 21 patents covering Prolia and Xgeva.
USFDA accepts Biologics License Application for proposed biosimilar denosumab: Sandoz Ruchika Sharma7 Feb 2023 10:15 AM ISTDenosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone...
Biocon Biologics collaborates with Yoshindo to commercialize bUstekinumab, bDenosumab in Japan Ruchika Sharma17 Oct 2022 2:30 PM ISTDenosumab, a biosimilar referencing Prolia, is a monoclonal antibody for the treatment of osteoporosis.
Lupin, DKSH ink pact to commercialize 5 of Alvotech proposed biosimilars in Philippines Ruchika Sharma7 Sept 2022 11:45 AM ISTThis agreement enhances Multicare's oncology, rheumatology, gastroenterology, and ophthalmology, portfolio, which currently consists of three...
Cipla Gulf expands partnership with Alvotech for commercialization of 4 biosimilar medicines in Australia, New Zealand Ruchika Sharma2 March 2021 4:26 PM ISTMumbai: Cipla Limited today announced that the company's subsidiary, Cipla Gulf FZ LCC ("Cipla Gulf') is expanding its partnership with Alvotech for...
